ACAD
39.245
+0.045
+0.115%
AEMD
3.882
+0.102
+2.7011%
APRI
3.05
-0.05
-1.61%
ARNA
1.44
-0.01
-0.69%
ATEC
3.09
0.00
0.00%
CNAT
4.83
-0.24
-4.7357%
CRXM
0.22
-0.03
-13.73%
CYTX
1.76
+0.01
+0.57%
DXCM
78.68
-1.22
-1.53%
GNMK
10.78
+0.23
+2.18%
HALO
12.185
-0.325
-2.598%
ILMN
163.048
+0.898
+0.5535%
INNV
0.155
-0.005
-3.125%
INO
6.69
-0.11
-1.6191%
ISCO
1.02
+0.01
+0.99%
ISIS
57.56
0.00
0.00%
LGND
103.6
-1.71
-1.62%
LPTN
2.93
0.00
0.00%
MBVX
2.791
-0.069
-2.4196%
MEIP
1.72
-0.01
-0.58%
MNOV
6.005
-0.035
-0.579%
MRTX
5.925
-0.225
-3.659%
MSTX
0.125
-0.001
-0.8696%
NBIX
43.69
-0.21
-0.48%
NUVA
73.81
-0.18
-0.24%
ONCS
1.51
+0.11
+7.8429%
ONVO
2.91
-0.09
-3.00%
OREX
4.2
-0.04
-0.94%
OTIC
15.4
-0.15
-0.96%
QDEL
21.33
+0.24
+1.14%
RCPT
231.96
0.00
0.00%
RGLS
1.075
-0.025
-2.273%
RMD
72.07
-0.14
-0.19%
SPHS
2.61
-0.05
-1.88%
SRNE
5.275
+0.025
+0.476%
TROV
2.05
-0.05
-2.38%
VICL
2.16
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
11
+0.5
+4.76%
ACAD
39.245
+0.045
+0.115%
AEMD
3.882
+0.102
+2.7011%
APRI
3.05
-0.05
-1.61%
ARNA
1.44
-0.01
-0.69%
ATEC
3.09
0.00
0.00%
CNAT
4.83
-0.24
-4.7357%
CRXM
0.22
-0.03
-13.73%
CYTX
1.76
+0.01
+0.57%
DXCM
78.68
-1.22
-1.53%
GNMK
10.78
+0.23
+2.18%
HALO
12.185
-0.325
-2.598%
ILMN
163.048
+0.898
+0.5535%
INNV
0.155
-0.005
-3.125%
INO
6.69
-0.11
-1.6191%
ISCO
1.02
+0.01
+0.99%
ISIS
57.56
0.00
0.00%
LGND
103.6
-1.71
-1.62%
LPTN
2.93
0.00
0.00%
MBVX
2.791
-0.069
-2.4196%
MEIP
1.72
-0.01
-0.58%
MNOV
6.005
-0.035
-0.579%
MRTX
5.925
-0.225
-3.659%
MSTX
0.125
-0.001
-0.8696%
NBIX
43.69
-0.21
-0.48%
NUVA
73.81
-0.18
-0.24%
ONCS
1.51
+0.11
+7.8429%
ONVO
2.91
-0.09
-3.00%
OREX
4.2
-0.04
-0.94%
OTIC
15.4
-0.15
-0.96%
QDEL
21.33
+0.24
+1.14%
RCPT
231.96
0.00
0.00%
RGLS
1.075
-0.025
-2.273%
RMD
72.07
-0.14
-0.19%
SPHS
2.61
-0.05
-1.88%
SRNE
5.275
+0.025
+0.476%
TROV
2.05
-0.05
-2.38%
VICL
2.16
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
11
+0.5
+4.76%
Home » Archive by Category

Xconomy

PvP Biologics Raises $35M in a Lab-to-Pharma Deal with Takeda

January 5, 2017 – 7:27 am

[Corrected 1/5/17, 8:07 am to show company was spun out of UW two months ago.] A San Diego-based startup spun out from the University of Washington just two months ago is today announcing a $35…

[[Click headline to continue reading.]]

HLI Adds Cynthia Collins as CEO, Venter Moves to Executive Chairman

January 4, 2017 – 3:54 pm

Human genome pioneer J. Craig Venter, who disclosed last month he’s being treated for prostate cancer, is moving into a new role as executive chairman at Human Longevity (HLI), the San Diego genomics…

[[Click headline to continue reading.]]

Edico Genome’s Deal with Dell EMC Fits Partnership Strategy

January 4, 2017 – 5:53 am

San Diego’s Edico Genome is now in its fourth year as a startup, and well into the hard slog of striking partnership deals, generating revenue, and building a business. Founding CEO Pieter van Rooyen…

[[Click headline to continue reading.]]

Versant Closes on $400M Fund, Eyes More Biotech Deals in Europe

January 3, 2017 – 2:44 pm

Versant Ventures now has $400 million in its coffers to fuel its pursuit of early-stage healthcare technologies and startups, and it has a particular goal of expanding its investment approach in…

[[Click headline to continue reading.]]

Watching for NIH Innovation in 2017—and Drug Pricing, Trade Deals

January 2, 2017 – 12:00 am

With the inauguration of Donald Trump as president on January 20th, the editors asked some of our Xconomists to offer their thoughts on “How could the incoming administration significantly affect…

[[Click headline to continue reading.]]

Varmus, Sato on Steering De Blasio’s $500M Plan to Grow NY Biotech

December 30, 2016 – 12:15 pm

The idea that New York City could become a biotech powerhouse dates back to the late 1990s. It’s been a slow, tedious process, and it’s nowhere near complete, but from near and far, Harold…

[[Click headline to continue reading.]]

Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug

December 28, 2016 – 10:46 am

[Updated, 12/29/16, see below] Patients with spinal muscular atrophy got some good news last week when the FDA approved nusinersen (Spinraza), making it the first marketed drug ever for the rare and…

[[Click headline to continue reading.]]

Ionis, Biogen Make History With FDA Nod for Spine Disease Drug

December 23, 2016 – 4:26 pm

Patients with spinal muscular atrophy got an early Christmas present on Friday. The FDA approved nusinersen (Spinraza), making the drug the first-ever marketed treatment for the rare, potentially…

[[Click headline to continue reading.]]

Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More

December 23, 2016 – 5:00 am

You’ve probably seen the Internet memes. “When 2016 started, I looked like this. [Insert picture of young Leo DiCaprio.] Now I look like this. [Leo, with mountain beard, after…

[[Click headline to continue reading.]]

14 for ’17: Key Clinical Data To Watch For Next Year (Part 2)

December 22, 2016 – 4:45 am

We continue our look ahead to some of the clinical data due in 2017 that could shape healthcare practice and sway investor sentiment for years to come. Part one of our preview is here, with looks at…

[[Click headline to continue reading.]]